Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.67 |
| ▸ | MAPT | P10636 | 10/20 | 0.67 |
| ▸ | LMNA | P02545 | 5/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7805734 | 1.00 | GAA (0.69) | GAAMAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL7809573 | 0.98 | ALDH1A1 (0.67) | GAAMAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL3537059 | 0.87 | ALDH1A1 (0.68) | GAAMAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL7809589 | 0.87 | ALDH1A1 (0.68) | GAAMAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL25387575 | 0.86 | MAPT (0.56) | GAAMAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL7800552 | 0.85 | ALDH1A1 (0.69) | GAAMAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL14377101 | 0.84 | MAPT (0.57) | GAAMAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL21275165 | 0.84 | SMN1; SMN2 (0.59) | GAAMAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL28719920 | 0.84 | ALDH1A1 (0.50) | GAAMAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL690222 | 0.84 | MAPT (0.63) | GAAMAPK1ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012430-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-10 | — | — | US | disclosed |
| US-7705042-B2 | Class of arylamide compounds useful as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7705042-B2 | Class of arylamide compounds useful as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7705042-B2 | Class of arylamide compounds useful as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-27 | — | — | US | disclosed |
| EP-1807407-B1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-29 | — | — | EP | disclosed |
| EP-1807407-B1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-29 | — | — | EP | disclosed |
| US-7388017-B2 | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060100201-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | US | disclosed |
| US-20010005914-A1 | OXIDATION DYES | ANDREAS J. BITTNER | 2001-07-05 | — | — | US | disclosed |
| EP-0912160-A2 | OXIDATION DYES | Hans Schwarzkopf GmbH & Co. KG (DE) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998001106-A2 | OXIDATION DYES | HANS SCHWARZKOPF GMBH & CO. KG (DE) | 1998-01-15 | — | — | WO | disclosed |
| US-RE30798-E | BY REACTING 4-FLUORO-3-NITROANILINES WITH AMMONIA OR A PRIMARY OR SECONDARY AMINE | CLAIROL INCORPORATED (US) | 1981-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100201-A1 | Inhibitors of c-fms kinase | MUSK, FLT3, FES | GAA 3696/4885MAPK1 280/4885ALDH1A1 4796/4885 |
| US-20010005914-A1 | OXIDATION DYES | AOC1, CBR3, KRT18 | GAA 4430/4885MAPK1 817/4885ALDH1A1 26/4885 |
| US-20130012430-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE | HPN, PRSS1, PRSS3 | GAA 568/4885MAPK1 3335/4885ALDH1A1 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.